Structure Therapeutics said Monday that its experimental GLP-1 pill demonstrated a 1% lowering of blood glucose and slightly more than 3% weight loss relative to a placebo in a 12-week study involving participants with type 2 diabetes — results that are preliminary but don’t quite match a competing oral drug under development by Eli Lilly.
The Structure drug, called GSBR-1290, may have a tolerability advantage: Only one participant out of 36 dropped out of the study due to drug-related side effects — a 2.8% discontinuation rate that could prove to be an advantage if confirmed in larger studies.
GSBR-1290, taken once daily, belongs to the booming class of GLP-1 drugs that increase insulin production to lower blood sugar in people with diabetes and make people feel full after eating, leading to dramatic weight loss in people with obesity.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect